Sirinonthanawech Naraporn, Surichan Somchaiya, Namsai Aphinya, Puthavathana Pilaipan, Auewarakul Prasert, Kongchanagul Alita
Institute of Molecular Biosciences (MB), Mahidol University, 25/25 Phuttamonthon 4 Road, Salaya, Nakhon Pathom 73170, Thailand.
The Government Pharmaceutical Organization (GPO), 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.
J Virol Methods. 2016 Nov;237:154-158. doi: 10.1016/j.jviromet.2016.09.001. Epub 2016 Sep 3.
Formulation and quality control of trivalent live-attenuated influenza vaccine requires titration of infectivity of individual strains in the trivalent mix. This is usually performed by selective neutralization of two of the three strains and titration of the un-neutralized strain in cell culture or embryonated eggs. This procedure requires standard sera with high neutralizing titer against each of the three strains. Obtaining standard sera, which can specifically neutralize only the corresponding strain of influenza viruses and is able to completely neutralize high concentration of virus in the vaccine samples, can be a problem for many vaccine manufacturers as vaccine stocks usually have very high viral titers and complete neutralization may not be obtained. Here an alternative approach for titration of individual strain in trivalent vaccine without the selective neutralization is presented. This was done by detecting individual strains with specific antibodies in an end-point titration of a trivalent vaccine in cell culture. Similar titers were observed in monovalent and trivalent vaccines for influenza A H3N2 and influenza B strains, whereas the influenza A H1N1 strain did not grow well in cell culture. Viral interference among the vaccine strains was not observed. Therefore, providing that vaccine strains grow well in cell culture, this assay can reliably determine the potency of individual strains in trivalent live-attenuated influenza vaccines.
三价减毒活流感疫苗的配方和质量控制需要对三价混合疫苗中各毒株的感染性进行滴定。这通常是通过对三种毒株中的两种进行选择性中和,并在细胞培养物或鸡胚中对未中和的毒株进行滴定来实现的。该程序需要针对三种毒株中的每一种具有高中和效价的标准血清。对于许多疫苗制造商来说,获得仅能特异性中和相应流感病毒毒株且能够完全中和疫苗样品中高浓度病毒的标准血清可能是一个问题,因为疫苗库存通常具有非常高的病毒滴度,可能无法实现完全中和。本文提出了一种无需选择性中和即可滴定三价疫苗中各毒株的替代方法。这是通过在细胞培养中对三价疫苗进行终点滴定,用特异性抗体检测各毒株来实现的。在甲型H3N2流感和乙型流感的单价疫苗和三价疫苗中观察到了相似的滴度,而甲型H1N1流感毒株在细胞培养中生长不佳。未观察到疫苗毒株之间的病毒干扰。因此,只要疫苗毒株在细胞培养中生长良好,该测定法就能可靠地测定三价减毒活流感疫苗中各毒株的效力。